Clinical Trial

Hemay005 for the Treatment of Chinese Moderately to Severely Active Ulcerative Colitis

Name: Hemay005 for the Treatment of Chinese Moderately to Severely Active Ulcerative Colitis — clinical trial record (NCT07650942)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

The purpose of this phase III, multicenter, double-blind, placebo-controlled study is to evaluate the efficacy and safety of Hemay005 compared to placebo as induction and maintenance therapy in Chinese participants with moderately to severely active ulcerative colitis.

Trial Details

NCT Number	NCT07650942
Lead Sponsor	Ganzhou Hemay Pharmaceutical Co., Ltd
Conditions	Ulcerative Colitis (UC)
Enrollment	360 participants
Start Date	2026-06
Primary Completion	2028-05 (estimated)
Study Completion	2029-02 (estimated)
Updated on ClinicalTrials.gov	2026-06-16